CLOs on the Move

Chartiers Center

www.chartierscenter.org

 
Chartiers’ primary focus is the integration of physical health and mental health wellness to enhance the quality of life for all people with behavioral or intellectual/ and developmental disabilities. Chartiers operates programs for adults with inte...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

BPR-Bechtel

BPR-Bechtel is a Sherbrooke, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Caron Products and Services

Caron Products is a provider of incubators & chambers for cell growth and product environmental testing in biological research, scale-up culture, and drug and biological QA/QC testing. Caron`s products are integral to workflows ranging from cell & gene therapy to medical device manufacturing. Caron`s expanding resources, with manufacturing facilities in both the USA and Europe, and a worldwide network of sales and service personnel aligns with the needs of the global biomedical industry.

Auburn Pharmaceutical

Auburn Pharmaceutical is a national full line generics wholesaler that purchases all of its products directly from 100+ manufacturers and is licensed across the Continental United States.

Family Care Network

We would love to hear from you! Please private message us with questions or feedback and we will respond as quickly as possible. General guidelines for posting on our page: • Be humane: Behind the computer screen, there are real humans with real fee...

Ripple Therapeutics

The Ripple Therapeutics Epidel® technology is founded on a discovery that drugs can be engineered into controlled release materials without the use of polymers or excipients. The proprietary prodrugs are new chemical entities (NCEs) that have unique properties that allow them to be processed into standalone drug delivery implants (e.g. intravitreal implants, micro/nanoparticles, etc.) or as coatings on medical devices. Ripple Therapeutics implants and coatings are made up entirely from the prodrug without a polymeric carrier to control the implant or drug release properties. The implants and coatings undergo surface erosion to give zero order drug release profiles and are highly engineerable (e.g. different forms, shapes, and sizes) to tailor drug dose and duration for the specific indication of interest. The flexibility in molecular design results in drug doses that are within the therapeutic window, delivering the right amount of drug for the right amount of time. This has the potential to improve patient safety and clinical outcomes.